首页 > 市场调查报告书 > 医疗设备

导管

市场调查报告书

商品编码

1316279

全球子宫内膜消融器械市场 - 2023-2030 年

Global Endometrial Ablation Devices Market - 2023-2030

出版日期: 2023年07月27日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概述

2022 年，全球子宫内膜消融器市场规模达到 35 亿美元，预计到 2030 年将实现 54 亿美元的丰厚增长。在预测期内（2023-2030 年），全球子宫内膜消融器械市场的复合年增长率预计将达到 5.6%。

子宫内膜消融器之所以重要，是因为它能有效治疗月经出血过多或经期延长的妇女，一般称为月经过多。月经过多会造成身体不适、精神痛苦和日常活动中断，从而对妇女的生活质量产生负面影响。

子宫内膜消融装置为希望保留子宫或避免大手术危害的妇女提供了子宫切除术之外的一种非手术选择。它能让患者在无需接受侵入性更强的手术的情况下治疗自己的问题。

市场动态

子宫内膜癌发病率上升

子宫内膜癌发病率的上升是帮助市场在预测期内进一步增长的重要关键驱动因素之一。例如，根据《2022 年美国社区调查》更新的情况说明书，美国有超过 60 万名子宫内膜癌幸存者。根据同一资料来源，预计 2022 年将发现约 65,950 例新的子宫体癌（子宫体癌或子宫体癌）病例。因此，子宫内膜癌发病率的上升预计将推动子宫内膜消融设备需求的增长。

妇科疾病发病率上升

女性宫颈癌、月经过多、异常阴道出血和多囊卵巢综合症（POCD）等妇科疾病发病率的上升是推动市场增长的主要因素。根据世界卫生组织 2022 年 2 月的最新数据，宫颈癌是全球妇女第四大常见癌症，到 2020 年将有 604 000 例新发病例和 342 000 例死亡病例。到 2020 年，中低收入国家的新增病例和死亡人数占全球的近 90%。因此，在预测期内，妇科疾病发病率的增加预计将推动市场增长。

子宫内膜消融术的相关风险

虽然不常见，但在手术过程中或手术后不久可能会出现以下风险。子宫深部损伤，如子宫肌层穿孔（撕裂）或烧伤；腹部器官损伤，如肠或膀胱穿孔（撕裂）或烧伤感染；阴道、外阴和皮肤烧伤出血（失血）；空气或气体栓塞（血管中的气泡）。

COVID-19 影响分析

在 COVID-19 流行期间，所有门诊治疗都被推迟或限制，以尽量减少病毒传播的危险，因为大多数慢性疗法都被认为是自愿的。根据 2022 年 9 月发表在《施普林格期刊》上的一篇文章，在 COVID-19 大流行期间，子宫内膜异位症患者的治疗次数受到限制，尤其是在第一次封锁期间。

子宫内膜异位症门诊量减少了 37%，子宫内膜异位症手术量减少了 90%。因此，在 COVID-19 期间，子宫内膜咨询和外科手术的减少对大流行初期的市场增长产生了重大影响。

俄乌战争影响分析

据估计，俄乌冲突对全球子宫内膜消融器市场的影响不大，原因是该地区子宫内膜消融器的普及率较低，而且没有主要的市场参与者。不过，在预测期内，子宫内膜消融器的进出口对全球子宫内膜消融器市场增长的影响预计不大。

Market Overview

The global endometrial ablation device market reached US$ 3.5 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 5.4 billion by 2030. The global endometrial ablation devices market is expected to exhibit a CAGR of 5.6% during the forecast period (2023-2030).

Endometrial ablation devices are significant because they can effectively treat women who have excessive or extended menstrual bleeding, generally known as menorrhagia. Menorrhagia can have a negative influence on a woman's quality of life by producing physical discomfort, mental anguish, and interruption of everyday activities.

Endometrial ablation devices provide a non-surgical option to hysterectomy for women who want to keep their uterus or avoid the hazards of major surgery. It enables patients to treat their problems without having to undergo more intrusive surgery.

Market Dynamics

Rising Prevalence of Endometrial Cancer

The rising prevalence of endometrial cancer is one of the significant key drivers that help the market to grow further during the forecast period. For instance, according to the American Community Survey 2022 updated factsheet, there were over 600,000 endometrial cancer survivors in the United States. According to the same source, around 65,950 new cases of uterine body cancer (uterine body or corpus) are projected to be detected in 2022. As a result, the rising incidence of endometrial cancer is predicted to drive up demand for endometrial ablation devices.

Rise in the Prevalence of Gynaecological Disorders

The rise in the prevalence of gynaecological disorders such as cervical cancer, menorrhagia, abnormal vaginal bleeding, and POCD (polycystic ovarian disease) in women is a major factor driving market growth. Cervical cancer is the fourth most common cancer in women worldwide, according to World Health Organization updates in February 2022, with 604 000 new cases and 342 000 deaths by 2020. Low- and middle-income countries accounted for nearly 90% of new cases and deaths globally by 2020. As a result, the increasing prevalence of gynaecological diseases is expected to drive market growth during the forecast period.

Risks Associated With Endometrial Ablation

While uncommon, the following risks may occur during or shortly after the surgery. Deep uterine damage, such as perforation (tear) or burn beyond the uterine muscle layer, injury to the abdominal organs, such as bowel or bladder perforation (tears) or burns infection, burn harm to the vagina, vulva, and skin haemorrhage (blood loss), embolism of air or gas (air bubble in the blood vessels) can occur.

COVID-19 Impact Analysis

During the COVID-19 epidemic, all outpatient treatments were postponed or limited to minimise the danger of viral transmission, as most chronic therapies were deemed voluntary. According to an article published in the Springer Journal in September 2022, during the COVID-19 pandemic, the number of treatments for endometriosis patients was limited, particularly during the first lockdown.

There was a 37% decrease in the endometriosis outpatient department and a 90% decrease in surgical endometriosis. Thus, the drop in endometrial consultations and surgical operations during COVID-19 had a substantial influence on market growth during the pandemic's early phases.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global endometrial ablation devices market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of endometrial ablation devices is expected to have little influence over the global endometrial ablation devices market growth over the forecast period.

Segment Analysis

The global endometrial ablation devices market is segmented based on device type, end user and region.

Hysteroscopy Devices from Device Type Segment Accounts for 23.6% of Market Share

The hysteroscopy devices from the device type segment with around 23.6%. The use of a hysteroscopy instrument offers a real-time picture of the uterine cavity, allowing the clinician to correctly plan and direct the endometrial ablation operation. The hysteroscope aids in visualising the position and extent of the endometrial tissue to be treated, allowing for accurate targeting and total coverage during the ablation procedure. Hysteroscopy instruments allow for continuous monitoring of the treatment progress during the endometrial ablation operation.

For instance, in November 2022, in India, Medtronic introduced a novel instrument for diagnostic and surgical hysteroscopy. India Medtronic, a fully owned subsidiary of Medtronic plc, announced the debut of the TruClear system, a mechanical hysteroscopic tissue removal device used for the safe and effective treatment of intrauterine abnormalities (IUA). Fibroids, polyps, retained products of conception, adhesions, malignancies, or hyperplasia are all examples of IUA.

Geographical Analysis

North America Accounted for Approximately 38.2% of the Market Share

North America is estimated to hold about 38.2% of the total market share throughout the forecast period due to the rising prevalence of gynaecological disorders such as PCOS, abnormal uterine bleeding (AUB), menorrhagia, and escalating cases of cancer such as uterine cancer among women is driving the North American endometrial ablation devices market, which is expected to grow positively.

Competitive Landscape

The major global players in the endometrial ablation devices market include: Medtronic, Boston Scientific Corporation, Cooper Surgical, Minerva Surgical, Ethicon, KARL STORZ GmbH & Co. KG, Richard Wolf GmbH, AngioDynamics Inc., Smith & Nephew PLC, Olympus Corporation and others.

Why Purchase the Report?

To visualize the global endometrial ablation devices market segmentation based on device type, end user and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the endometrial ablation devices market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global endometrial ablation devices market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Device Type
3.2. Snippet by End User
3.3. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Prevalence of Endometrial Cancer
  - 4.1.1.2. Rise in Approvals
- 4.1.2. Restraints
  - 4.1.2.1. Risks Associated With Endometrial Ablation
- 4.1.3. Opportunity
  - 4.1.3.1. Increasing technological advancements in endometrial ablation devices
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Device Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type
7.2. Hydrothermal ablators *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Thermal balloon ablators
7.4. Hysteroscopy devices
7.5. Cryoablation devices
7.6. Radiofrequency endometrial ablation devices
7.7. Microwave endometrial ablators
7.8. Others

8. By End User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.1.2. Market Attractiveness Index, By End User
8.2. Hospital *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Ambulatory surgical centres
8.4. Specialty Clinics
8.5. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.5.1. U.S.
  - 9.2.5.2. Canada
  - 9.2.5.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.5.1. Germany
  - 9.3.5.2. U.K.
  - 9.3.5.3. France
  - 9.3.5.4. Spain
  - 9.3.5.5. Italy
  - 9.3.5.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1. Brazil
  - 9.4.5.2. Argentina
  - 9.4.5.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1. China
  - 9.5.5.2. India
  - 9.5.5.3. Japan
  - 9.5.5.4. Australia
  - 9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Medtronic*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Boston Scientific Corporation
11.3. Cooper Surgical
11.4. Minerva Surgical
11.5. Ethicon
11.6. KARL STORZ GmbH & Co. KG
11.7. Richard Wolf GmbH
11.8. AngioDynamics Inc.
11.9. Smith & Nephew PLC
11.10. Olympus Corporation

LIST NOT EXHAUSTIVE